I've been in this for a little while now & myself didn't realise...

I've been in this for a little while now & myself didn't realise the extent to which this stock is under the radar!

This presentation puts it all together in a nice concise manner.

It has:
- A diagnostic test which is better then the current gold standard for Colon Cancer which is the 2nd most common cancer in the developed world
- An enormous addressable market of some 250m people which is worth $6bn+ for the global screening market alone
- The test is non-evasive, as opposed to the current gold standard test which is a faecal test
- Strong news flow for the remainder of 2018
- Strong news flow for 2019
- Well funded with 7m in the Bank

It is no wonder directors have been buying on market recently, along with their largest shareholder, Merchant Funds Management which have taken their stake to 8.1% now.

Given the above, I would dare say that a major partnership agreement with Big-Pharma isn't too far away and as the path towards commercialisation becomes clearer, the SP will be our best friend